Pfizer is preparing to present its case at the U.S. Patent and Trademark Office’s administrative board in a bid to contest patents held by Moderna. The pharmaceutical giant aims to challenge the validity of Moderna’s patents, which it argues cover “a basic idea” of using mRNA technology to combat the COVID-19 virus. This hearing, scheduled to take place next week, highlights an ongoing battle over intellectual property rights that have gained particular prominence due to the global pandemic.
The U.S. Patent Trial and Appeal Board (PTAB) will delve into Pfizer’s argument against Moderna’s claims to these patents, marking a critical juncture in the ongoing discussion around the protections afforded to mRNA technology which has played a pivotal role in the development of COVID-19 vaccines. Industry stakeholders and legal professionals will closely watch the outcome as it could have broad implications for patent law and pharmaceutical innovation.
For further details, the original article, titled “IP Forecast: PTAB To Hear Pfizer Fight Over COVID-19 Patents,” can be accessed here.